Looking For A Buyer, Savient Talks Krystexxa Price & Gears Up For Launch
Executive Summary
On the prowl for a buyer after the approval of Krystexxa for refractory gout, Savient Pharmaceuticals assured investors that they have enough product supply to launch by year-end and that it will set a premium price, though it was vague on when it will commit to an exact figure.